<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00317187</url>
  </required_header>
  <id_info>
    <org_study_id>100791</org_study_id>
    <nct_id>NCT00317187</nct_id>
  </id_info>
  <brief_title>Safety Study of a Vaccine Against Meningitis in Infants (2,4 &amp; 6 Months Age) After a Birth Dose of Hepatitis B.</brief_title>
  <official_title>Partially Blinded Study to Assess Reactogenicity &amp; Safety of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ in Healthy Infants After a Hepatitis B Birth Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the reactogenicity &amp; safety of
      Tritanrix™-HepB/Hib-MenAC vaccine to the international standard of care,
      Tritanrix™-HepB/Hiberix™.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized study with four groups to receive one of the following vaccination regimens after
      a dose of hepatitis B vaccine given at birth:

        -  One of the 3 lots of GSK Biologicals' Hib-MenAC mixed with GSK Biologicals'
           Tritanrix™-HepB (3 different groups)

        -  GSK Biologicals' Tritanrix™-HepB/Hiberix™
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Day 0-3 after each dose, fever &gt;38.5°C(axillary).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Solicited events other than fever (day 0-3); unsolicited events (day 0-30); serious adverse events (entire study).</measure>
  </secondary_outcome>
  <enrollment>500</enrollment>
  <condition>Hib Disease</condition>
  <condition>Hepatitis B</condition>
  <condition>Diphtheria</condition>
  <condition>Pertussis</condition>
  <condition>Neisseria Meningitidis Serogroup Diseases</condition>
  <condition>Tetanus</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTPw-HBV/Hib-MenAC conjugate vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        • Healthy infants 56-83 days of age at the time of the first vaccine dose, written informed
        consent obtained from the parents, born after a gestation period of 36 to 42 weeks &amp; has
        received a birth dose of hepatitis B vaccine within the first 3 days of life.

        Exclusion criteria:

          -  Any confirmed immunodeficient condition, based on medical history and physical
             examination.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             within 30 days before the first dose of study vaccine, or planned administration
             during the study period with the exception of oral polio vaccine (OPV).

          -  Use of any investigational or non-registered drug or vaccine other than the study
             vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use
             during the study period.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs since birth.

          -  Bacille Calmette-Guérin (BCG) vaccine received after the first 2 weeks of life.

          -  Previous vaccination against diphtheria, tetanus, pertussis, Haemophilus influenzae
             type b, and/or meningococcal disease.

          -  History of diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b
             and/or meningococcal disease or known exposure to these diseases since birth.

          -  Administration of immunoglobulins and/or any blood products since birth or planned
             administration during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>56 Days</minimum_age>
    <maximum_age>83 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2006</study_first_submitted>
  <study_first_submitted_qc>April 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2006</study_first_posted>
  <last_update_submitted>September 29, 2011</last_update_submitted>
  <last_update_submitted_qc>September 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2011</last_update_posted>
  <responsible_party>
    <name_title>Cheri Hudson; Clinical Disclosure Advisor</name_title>
    <organization>GSK Clinical Disclosure</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

